Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- P&G, Teva to Combine Their OTC Businesses
April 11, 2011
- OncoTherapy Begins Recruitment for Cancer Vaccine Trial
April 11, 2011
- Asahi Kasei Licenses XIAFLEX from Auxilium
April 4, 2011
- MREAC Calls For “Consideration”in Post-disaster MR Activities
April 4, 2011
- Kowa, MEDRx Announce Agreement for Etodolac Patch
April 4, 2011
- Recruiting Is the Lifeblood of Any Company
April 4, 2011
- Meiji Seika Licenses Ziprasidone from RaQualia
April 4, 2011
- Vaccination with Prevnar, ActHIB to Resume April 1
April 4, 2011
- R-Tech Ueno Licenses Unoprostone to Sucampo
April 4, 2011
- Pharma Design Licenses Part of Its Rights to Cancer Transcription Factors to Yakult
April 4, 2011
- BI Ties Up with MorphoSys to Manufacture Biopharmaceuticals
April 4, 2011
- Oncology Strategies of Top-four Japanese Pharmaceutical Companies
April 4, 2011
- Reminyl for AD: Takeda, Janssen
April 4, 2011
- Looking Back Over a Hectic Week for Vaccines
April 4, 2011
- Prazaxa to Mainly Target CV Specialists, Neurologists: NBI
April 4, 2011
- NIBIO to Promote Development of Next-generation Adjuvants
April 4, 2011
- New Drugs May Be Approved 1 Month Earlier from April
April 4, 2011
- Kitasato Daiichi Sankyo Vaccine Co., Ltd. Inaugurated
April 4, 2011
- Restrictions on Ex-company Employees of PMDA to Remain for Now
April 4, 2011
- Tokyo District Court Holds Both Gov't, AZ Responsible in Iressa Affair
April 4, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…